Moomoo AI 已提取核心信息
On December 31, 2023, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC, disclosing a 9.99% ownership stake in Vivos Therapeutics, Inc., amounting to 175,099 shares. Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over the securities held by the Master Fund. Steven Boyd, as the managing member of Armistice Capital, may also be deemed to beneficially own the securities held by the Master Fund. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Vivos Therapeutics. The filing was signed and dated February 14, 2024, by Steven Boyd, Managing Member of Armistice Capital, LLC.
On December 31, 2023, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC, disclosing a 9.99% ownership stake in Vivos Therapeutics, Inc., amounting to 175,099 shares. Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over the securities held by the Master Fund. Steven Boyd, as the managing member of Armistice Capital, may also be deemed to beneficially own the securities held by the Master Fund. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Vivos Therapeutics. The filing was signed and dated February 14, 2024, by Steven Boyd, Managing Member of Armistice Capital, LLC.
2023年12月31日，Armistice Capital, LLC和Steven Boyd向美国证券交易委员会提交了附表13G，披露了Vivos Therapeutics, Inc. 9.99％的所有权，共计175,099股。作为停战资本主基金有限公司的投资经理，停战资本对主基金持有的证券行使投票权和投资权。史蒂芬·博伊德作为停战资本的管理成员，也可能被视为实益拥有主基金持有的证券。文件显示，这些股份是在正常业务过程中收购的，不是为了改变或影响Vivos Therapeutics的控制权。该文件由停战资本有限责任公司管理成员史蒂芬·博伊德于2024年2月14日签署并注明日期。
2023年12月31日，Armistice Capital, LLC和Steven Boyd向美国证券交易委员会提交了附表13G，披露了Vivos Therapeutics, Inc. 9.99％的所有权，共计175,099股。作为停战资本主基金有限公司的投资经理，停战资本对主基金持有的证券行使投票权和投资权。史蒂芬·博伊德作为停战资本的管理成员，也可能被视为实益拥有主基金持有的证券。文件显示，这些股份是在正常业务过程中收购的，不是为了改变或影响Vivos Therapeutics的控制权。该文件由停战资本有限责任公司管理成员史蒂芬·博伊德于2024年2月14日签署并注明日期。
有用
没用